Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

Baseline characteristics and enrichment results from the SONAR trial

(2018) Hiddo J.L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Atrasentan Reduces Albuminuria by Restoring the Glomerular Endothelial Glycocalyx Barrier in Diabetic Nephropathy

(2016) Margien G.S. Boels et al.   DIABETES

Is a reduction in albuminuria associated with renal and cardiovascular protection? Apost hocanalysis of the ALTITUDE trial

(2016) H. J. L. Heerspink et al.   DIABETES OBESITY & METABOLISM

Unmet need in diabetic nephropathy: failed drugs or trials?

(2016) Dick de Zeeuw et al.   Lancet Diabetes & Endocrinology

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers

(2015) Bauke Schievink et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy

(2015) D. E. Kohan et al.   Clinical Journal of the American Society of Nephrology

Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View

(2015) H. J. Lambers Heerspink et al.   Clinical Journal of the American Society of Nephrology

ET and Diabetic Nephropathy: Preclinical and Clinical Studies

(2015) Elena Gagliardini et al.   SEMINARS IN NEPHROLOGY

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

(2015) Bauke Schievink et al.   European Journal of Preventive Cardiology

Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist

(2014) J. Hoekman et al.   Clinical Journal of the American Society of Nephrology

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

(2014) H. J. Lambers Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

(2014) D. de Zeeuw et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

(2013) Dick de Zeeuw et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial

(2013) Hiddo J Lambers Heerspink et al.   European Journal of Preventive Cardiology

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sulodexide Fails to Demonstrate Renoprotection in Overt Type 2 Diabetic Nephropathy

(2011) D. K. Packham et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Phase III and submission failures: 2007–2010

(2011) John Arrowsmith   NATURE REVIEWS DRUG DISCOVERY

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

(2010) Y. Miao et al.   DIABETOLOGIA

Avosentan for Overt Diabetic Nephropathy

(2010) J. F.E. Mann et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria

(2009) R. R. Wenzel et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

(2009) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE